Equol, combined with estrogen receptors, can reduce the incidence of diseases such as cardiovascular disease, osteoporosis, and breast cancer; more effectively alleviate the symptoms of perimenopausal syndrome; and improve age‐related decline of the uterus and ovaries. This evidence concerns the gene ESR1 and breast carcinoma.